多西他赛单药一线治疗晚期非小细胞肺癌疗效观察

目的探讨多西他赛单药一线治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法将60例老年晚期NSCLC初治患者作为治疗组,另选同期初治拒绝接受化疗患者30例作为对照组。治疗组予多西他赛单药治疗,对照组予最佳支持治疗。比较2组近期疗效、远期疗效、生活质量及毒性反应。结果治疗组有效率、临床受益率显著高于对照组,中位TTP（5.8个月）、中位OS（11.2个月）较对照组（2.6个月、4.6个月）显著延长;治疗组1年生存率（40.0%）显著高于对照组（10.0%）;治疗组药物毒性反应较轻。结论多西他赛单药一线治疗晚期NSCLC患者安全有效,值得临床推广应用。

Clinical observation of docetaxel single-agent in the first-line treatment of advanced non-small cell lung cancer

Objective To explore the efficacy and safety of docetaxel single-agent in the first-line treatment of advanced non-small cell lung cancer（NSCLC）.Methods Sixty elderly patients with advanced NSCLC were divided into treatment group,and the other 30 patients in the same period who refused to receive chemotherapy were used as control group.The treatment group received docetaxel single-agent,and the control group received best supportive care.The short-term and long-term effects,quality of life and toxic reactions were compared.Results The efficacy rate（ER） and clinical benefit response（CBR） were obviously higher in the treatment group than in the control group.The median TTP（5.8 months） and median OS（11.2 months） were obviously longer in the treatment group than in the control group（2.6 months,4.6 months）.The one-year survival rate（40.0%） was obviously higher in the treatment group than in the control group（10.0%）.The toxic reactions in the treatment group were slight.Conclusion The single-agent docetaxel in the first-line treatment of NSCLC is effective,safe,and worthy to be popularized in clinical application.